Linaclotide — Hyped or Proven?

What Linaclotide is

Linaclotide is a peptide medicine used in approved gastrointestinal contexts through guanylate cyclase-C signaling.

Linaclotide is grouped under Approved / Clinical on PeptideFactCheck because it broadens the site into real peptide GI pharmacology beyond research-peptide culture.

The useful starting point is to separate the molecule itself from the internet story around it. It broadens the site into real peptide GI pharmacology beyond research-peptide culture.

Why people keep looking it up

It broadens the site into real peptide GI pharmacology beyond research-peptide culture.

Linaclotide is a peptide medicine used in approved gastrointestinal contexts through guanylate cyclase-C signaling.

Linaclotide tends to stay in the conversation because it touches a familiar public theme: guanylate cyclase-c, gi motility, and intestinal secretion. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

Approved peptide drug with direct human and label support.

Human trials and labeling support specific approved uses.

Mechanistic rationale aligns with intestinal secretion and motility signaling.

Why this page carries the current tier: Approved peptide drug with direct human and label support.

The current seed trail for Linaclotide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.

Safety, limits, and regulatory context

Approved GI-drug use should be read through the label rather than generalized into vague gut-health language.

FDA-approved linaclotide products exist for specific indications.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Linaclotide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for Linaclotide is CID 16158208. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID: 16158208
Formula: C59H79N15O21S6
Molecular weight: 1526.8
InChIKey: KXGCNMMJRFDFNR-WDRJZQOASA-N

Matched synonyms include Linaclotide, Linzess, 851199-59-2, Constella, Linaclotida, N0TXR0XR5X, CHEBI:68551, ASP0456.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for Linaclotide returns 58 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With ConstipationNCT02559817 | TERMINATED | PHASE2Forest Laboratories | first posted 2015-09-24Open trial Caecal pH as a Biomarker for Irritable Bowel SyndromeNCT02360384 | UNKNOWN | NAWingate Institute of Neurogastroenterology | first posted 2015-02-10Open trial Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic ConstipationNCT00306748 | COMPLETED | PHASE2Ironwood Pharmaceuticals, Inc. | first posted 2006-03-24Open trial Linaclotide for Colonoscopy Bowel PrepNCT06692673 | RECRUITING | PHASE1, PHASE2University of Florida | first posted 2024-11-18Open trial Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional ConstipationNCT04110145 | COMPLETED | PHASE2Allergan | first posted 2019-10-01Open trial

Literature snapshot

The current PubMed query for Linaclotide returns 489 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Irritable bowel syndrome.Medicina clinica | 2022 Jan 21Sebastián Domingo JJ | DOI 10.1016/j.medcli.2021.04.029Open citation Diagnosis and management of chronic constipation in adults.Nature reviews. Gastroenterology & hepatology | 2016 MayRao SS, Rattanakovit K, Patcharatrakul T | DOI 10.1038/nrgastro.2016.53Open citation American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.Gastroenterology | 2023 JunChang L, Chey WD, Imdad A, Almario CV | DOI 10.1053/j.gastro.2023.03.214Open citation Management of Constipation in Older Adults.American family physician | 2015 Sep 15Mounsey A, Raleigh M, Wilson AOpen citation Linaclotide (Linzess) for functional constipation.The Medical letter on drugs and therapeutics | 2023 Aug 21Author list not linked | DOI 10.58347/tml.2023.1683dOpen citation

Label and regulatory records

For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.

Brand names: Linzess
Generic names: LINACLOTIDE
Routes: ORAL
Application numbers: NDA202811

Indications and usage. 1 INDICATIONS AND USAGE LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older • chronic idiopathic constipation (CIC) in adults • functional constipation (FC) in pediatric patients 6 years of age and older LINZESS is a guanylate cyclase-C agonist indicated for treatment of: Irritable bowel syndrome with constipation (...

Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Diarrhea: Patients may experience severe diarrhea. If severe diarrhea occurs, suspend dosing and rehydrate the patient. ( 5.2 ) 5.1 Risk of Serious Dehydration in Pediatric Patients Less Than 2 Years of Age LINZESS is contraindicated in patients less than 2 years of age. In neonatal mice (human age equivalent of approximately 0 to 28 days), linaclotide increased fluid secretion as a conseq...

Contraindications. 4 CONTRAINDICATIONS LINZESS is contraindicated in: Patients less than 2 years of age due to the risk of serious dehydration [see Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.4 )] . Patients with known or suspected mechanical gastrointestinal obstruction. Patients less than 2 years of age. ( 4 , 5.1 , 8.4 ) Patients with known or suspected mechanical gastrointestinal obstruction. ( 4 )

LINZESS (LINACLOTIDE) CAPSULE, GELATIN COATED [ALLERGAN, INC.]Jan 16, 202609beda19-56d6-4a56-afdc-9a77b70b2ef3Open label

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

DailyMed label searchLabelUsed here for official marketed labeling, indications, route, and warnings.Open source FDA Orange BookRegulatoryUsed here for approval, Orange Book, or broader regulatory-status context.Open source PubMed literature searchCitationUsed here to check published human studies, reviews, and preclinical literature.Open source

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.